PEGBIO CO-B (02565) announced its interim results for the six months ended June 30, 2025. The group recorded other net income of RMB 178,000 (all amounts in RMB), R&D expenses of RMB 26.294 million, and a loss per share of RMB 0.25.

As of the announcement date, the company has made significant progress in advancing technological innovation, product pipeline, and business operations in both the United States and China. PEGBIO CO-B has successfully established a pipeline matrix covering 6 drug candidates targeting chronic disease areas.

The company's core strategy focuses on the treatment of metabolic diseases and their complications. Through continuous innovation, internal assessments indicate that multiple drug candidates possess dual value potential as both "first-in-class" (FIC) and "best-in-class" (BIC), establishing a solid foundation for future market competitiveness.

With PB-119's New Drug Application (NDA) having been accepted by the National Medical Products Administration, the company expects to commercialize PB-119 in China in the near future. Following market launch, the company anticipates incurring costs related to operating as a listed company.

Due to the development status of drug candidates, potential collaboration timelines and terms with partners, regulatory approval schedules, and commercialization of drug candidates, the company expects its financial performance to fluctuate across different periods.